| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $362,615 | 14 | 100 |
Sells | $0 | 0 | 0 |
| Seizinger Bernd R. | director | 3 | $187,224 | 0 | $0 | $187,224 |
| Kelly Jared | Chief Executive Officer | 3 | $34,369 | 0 | $0 | $34,369 |
| Andrews Patricia S | director | 1 | $30,292 | 0 | $0 | $30,292 |
| Aromando Andrew | Chief Business Officer | 1 | $25,418 | 0 | $0 | $25,418 |
| Pisano Wayne | director | 1 | $25,338 | 0 | $0 | $25,338 |
| Brown Deborah Margaret | director | 1 | $21,240 | 0 | $0 | $21,240 |
| Parsons James T. | director | 1 | $10,300 | 0 | $0 | $10,300 |
| Look Kirk | Chief Financial Officer | 1 | $10,104 | 0 | $0 | $10,104 |
| Heineman Thomas Charles | Chief Medical Officer | 1 | $10,033 | 0 | $0 | $10,033 |
| Hagerman Allison | VP, Product Development | 1 | $8,298 | 0 | $0 | $8,298 |
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing …
Over the last 12 months, insiders at Oncolytics Biotech Inc. have bought $362,615 and sold $0 worth of Oncolytics Biotech Inc. stock.
On average, over the past 5 years, insiders at Oncolytics Biotech Inc. have bought $362,615 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Seizinger Bernd R. (director) — $187,224. Kelly Jared (Chief Executive Officer) — $34,369. Andrews Patricia S (director) — $30,292.
The last purchase of 5,050 shares for transaction amount of $4,848 was made by Kelly Jared (Chief Executive Officer) on 2026‑03‑12.
| 2026-03-12 | Kelly Jared | Chief Executive Officer | 5,050 0.005% | $0.96 | $4,848 | -12.14% | ||
| 2026-03-11 | Parsons James T. | director | 10,000 0.0102% | $1.03 | $10,300 | -16.18% | ||
| 2026-02-12 | Seizinger Bernd R. | director | 40,000 0.0404% | $0.85 | $33,864 | +2.57% | ||
| 2026-02-12 | Pisano Wayne | director | 30,000 0.0302% | $0.84 | $25,338 | +2.57% | ||
| 2026-02-12 | Look Kirk | Chief Financial Officer | 12,000 0.0121% | $0.84 | $10,104 | +2.57% | ||
| 2026-02-12 | Heineman Thomas Charles | Chief Medical Officer | 12,132 0.012% | $0.83 | $10,033 | +2.57% | ||
| 2026-02-12 | Hagerman Allison | VP, Product Development | 10,000 0.0099% | $0.83 | $8,298 | +2.57% | ||
| 2026-02-12 | Brown Deborah Margaret | director | 25,000 0.0254% | $0.85 | $21,240 | +2.57% | ||
| 2026-02-12 | Kelly Jared | Chief Executive Officer | 29,500 0.0297% | $0.84 | $24,839 | +2.57% | ||
| 2026-02-12 | Andrews Patricia S | director | 35,400 0.0362% | $0.86 | $30,292 | +2.57% | ||
| 2026-02-11 | Seizinger Bernd R. | director | 60,000 0.0579% | $0.83 | $49,590 | +0.27% | ||
| 2026-02-11 | Kelly Jared | Chief Executive Officer | 5,600 0.0055% | $0.84 | $4,682 | +0.27% | ||
| 2026-02-11 | Aromando Andrew | Chief Business Officer | 29,600 0.0297% | $0.86 | $25,418 | +0.27% | ||
| 2026-01-16 | Seizinger Bernd R. | director | 100,000 0.0999% | $1.04 | $103,770 | -14.34% |
| Increased Positions | 23 | +39.66% | 672,967 | +23.88% |
| Decreased Positions | 12 | -20.69% | 680,659 | -24.16% |
| New Positions | 13 | New | 596,915 | New |
| Sold Out Positions | 7 | Sold Out | 554,706 | Sold Out |
| Total Postitions | 69 | +18.97% | 3M | -0.27% |